| Identification | Back Directory | [Name]
Benzoic acid, 5-(2-broMoacetyl)-2-hydroxy-, Methyl ester | [CAS]
36256-45-8 | [Synonyms]
Labetalol Impurity 8 Methyl 5-(bromoacetyl)salicylate 3-CarboMethoxy-4-hydroxy-α-broMoacet Methyl 5-(bromoacetyl)-2-hydroxybenzoate 5-(Bromoacetyl)salicylic acid methyl ester Methyl 5-(2-broMoacetyl)-2-hydroxybenzoate 3-CarboMethoxy-4-hydroxy-α-broMoacetophenone 3-Carbomethoxy-4-hydroxy-a-bromoacetophenone 5-(2-BroMoacetyl)-2-hydroxyl benzoic acid Methyl ester Benzoic acid, 5-(2-broMoacetyl)-2-hydroxy-, Methyl ester | [Molecular Formula]
C10H9BrO4 | [MDL Number]
MFCD09833483 | [MOL File]
36256-45-8.mol | [Molecular Weight]
273.08 |
| Chemical Properties | Back Directory | [Melting point ]
91-92℃ | [Boiling point ]
390.2±32.0 °C(Predicted) | [density ]
1.601±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
7.52±0.20(Predicted) | [color ]
Off-White to Pale Brown |
| Hazard Information | Back Directory | [Uses]
3-Carbomethoxy-4-hydroxy-α-bromoacetophenone, can be used for the synthesis of carboxyarylindoles and benzofurans as nonsteroidal antiinflammatory agents. | [Preparation]
Obtained by reaction of dioxane dibromide with methyl 5-acetyl-2-hydroxybenzoate in dioxane/ethyl ether mixture (76%). | [Synthesis]
Methyl 5-acetyl-2-hydroxybenzoate (1.0 g, 5.1 mmol) was used as starting material, which was dissolved in a mixed CHCl3/EtOAc solvent (40 mL), and copper (II) bromide (2.4 g, 10.8 mmol) was added under stirring. The reaction mixture was gently refluxed at 40-50 °C for 4 h. The reaction process was monitored by thin layer chromatography (TLC). Upon completion of the reaction, the reaction mixture was filtered and subsequently extracted by adding water (50 mL) and EtOAc (40 mL). The EtOAc layer was separated and the aqueous layer was further extracted with EtOAc (20 mL x 2). All EtOAc extracts were combined, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to give the crude product, methyl 5-(2-bromoacetyl)-2-hydroxybenzoate, as a yellow-white solid. The crude product was purified by recrystallization from dichloromethane and hexane to afford the target compound, methyl 5-(2-bromoacetyl)-2-hydroxybenzoate (2), as a white solid (1.2 g, yield about 85%, purity about 95%). The spectral data (1H NMR) of the obtained compound were in agreement with literature reports: 1H NMR (400 MHz, CDCl3) δ (ppm): 11.35 (s, 1H), 8.53 (d, J = 2.3 Hz, 1H), 8.12 (dd, J = 8.8, 2.2 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 4.41 ( s, 2H), 4.02 (s, 3H). | [References]
[1] European Journal of Medicinal Chemistry, 2017, vol. 136, p. 452 - 456 [2] Patent: WO2017/120193, 2017, A1. Location in patent: Page/Page column 53 [3] Journal of Medicinal Chemistry, 1981, vol. 24, # 3, p. 327 - 336 [4] Journal of Medicinal Chemistry, 1980, vol. 23, # 7, p. 738 - 744 [5] Canadian Journal of Chemistry, 2011, vol. 89, # 3, p. 364 - 384 |
|
| Company Name: |
Aruvi Labs
|
| Tel: |
+91-8056181939 |
| Website: |
www.www.NOWEBSITE |
| Company Name: |
NovoChemy Ltd.
|
| Tel: |
86-(0)21-31261262 373522135 |
| Website: |
www.novochemy.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|